A month’s supply of covered insulin costs Medicare beneficiaries no more than $35, with no deductible to meet first. The cap applies to each covered insulin product a person uses, under both the drug benefit and the medical benefit, and it holds even for those who qualify for low-income assistance. For a retiree who once paid hundreds of dollars a month for insulin, the limit is among the most tangible cost changes Medicare has delivered in recent years, and it is written into federal law rather than set plan by plan.
How the $35 cap works
The rule is straightforward. Medicare limits the cost of a one-month supply of each covered insulin product to $35, and it waives the deductible that would normally apply before drug coverage begins. The cap is per product, so a person who uses more than one type of covered insulin pays no more than $35 for each in a given month. There is no separate approval process; the limit applies automatically to covered insulin at the pharmacy counter.
The change marks a sharp break from the recent past. Before the cap, insulin costs varied by plan and by the phase of a person’s drug coverage, and out-of-pocket charges for a single vial or box of pens could reach well over $100, climbing higher for people who used multiple products. Fixing the monthly figure at $35 removed both the size of the bill and its unpredictability from one month to the next.
The same ceiling carries over to multi-month fills. A beneficiary who picks up a three-month supply pays no more than $35 for each month’s supply, or about $105 for the quarter, according to Medicare’s insulin coverage rules. That structure prevents a large upfront bill at the start of the year, the point at which insulin costs used to spike before other protections took effect.
Free retirement updates: Want plain-English help keeping more of your money in retirement? The free Retirement Shield newsletter covers the benefits, deadlines, and money mistakes that cost retirees, a couple times a week. Subscribe free.
Part B and Part D cover different insulin
Which part of Medicare pays depends on how the insulin is delivered. Part B, the medical benefit, covers insulin used with a traditional insulin pump that qualifies as durable medical equipment, as described in what Part B covers. It does not cover insulin taken by pen or needle, disposable patch pumps, or the related supplies, which fall outside the equipment benefit.
Most people who inject insulin rely on the drug benefit instead. Part D plans cover injectable insulin taken with a pen or needle, inhaled insulin, insulin used with disposable patch pumps, and supplies such as syringes and needles, and the $35 monthly cap applies across that coverage, as Medicare details in its Part D cost rules. The split matters because a person’s device determines which benefit sets the price, though the $35 ceiling reaches both routes.
What the cap does and does not change
The limit is unusually broad in who it protects. It applies to every beneficiary who takes covered insulin, including those enrolled in the Extra Help program for low-income members, so qualifying for other assistance does not reduce or remove the $35 protection. For someone with Part B and a Medigap policy that pays the Part B coinsurance, that supplement should cover the insulin cost under the equipment benefit.
The cap also has edges. It applies to insulin a plan covers, so a specific product left off a plan’s drug list may not qualify, which makes checking a plan’s formulary worthwhile before assuming the $35 figure applies. Insulin-related supplies billed under Part B, such as syringes and gauze for pump users, can carry their own costs outside the $35 amount. The protection is real but tied to covered products and the benefit that pays for them.
The cap does not touch the underlying list price of insulin or a plan’s monthly premium; it limits only what a beneficiary pays for the product at the counter. A person still owes the plan’s premium, and the broader cost of managing diabetes extends to monitors, test strips, and doctor visits that follow their own coverage rules. The $35 figure solves one large and once-volatile expense, not the full cost of the condition.
The cap did not always exist. It took effect for Medicare drug plans in 2023 under the 2022 federal law, and later that year the same $35 monthly limit was extended to insulin used with pumps covered under the medical benefit. Because the figure is fixed by statute rather than reset by insurers each year, it has stayed at $35 while many other Medicare costs have drifted upward from one year to the next.
The insulin cap stands out because it replaced an open-ended cost with a fixed, predictable one, and it did so through federal law rather than the year-to-year choices of individual plans. That legal footing is why the $35 figure has held steady rather than drifting with each plan’s pricing. For the millions of older Americans who depend on insulin, the practical effect is a number they can count on at the pharmacy, provided the product they use is one their plan covers.
This article was researched and drafted with the assistance of AI and reviewed by The Money Overview editorial team.
More Financial Reading
